Brentuximab vedotin is a CD30-targeted immunoconjugate that was effective in a phase II trial of relapsed, refractory peripheral T cell lymphoma and AITL (64), both of which exhibit high expression of CD30. This evidence concerns the gene TNFRSF8 and angioimmunoblastic T-cell lymphoma.